Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease

Imhof, Armin; Rothenbacher, Dietrich; Khuseyinova, Natalie; Hoffmeister, Albrecht; Maerz, Winfried; Nauck, Matthias; Scharnagl, Hubert; Köenig, Wolfgang; Brugger, Hermann

doi:10.1097/01.hjr.0000087080.83314.be

Cited by 24 publications

(16 citation statements)

References 54 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relationship between Lp(a) levels and the severity of coronary atherosclerosis in patients with unstable angina or acute myocardial infarction (MI) has been analyzed in several studies with controversial results [77–79]. The potential value of small apo(a) isoforms in predicting severe angiographically demonstrable atherosclerosis remains unclear.…”

Section: Lp(a) and Cardiovascular Diseasesmentioning

confidence: 99%

Lipoprotein(a) in Cardiovascular Diseases

Malaguarnera

Vacante

Russo

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Lipoprotein(a) (Lp(a)) is an LDL-like molecule consisting of an apolipoprotein B-100 (apo(B-100)) particle attached by a disulphide bridge to apo(a). Many observations have pointed out that Lp(a) levels may be a risk factor for cardiovascular diseases. Lp(a) inhibits the activation of transforming growth factor (TGF) and contributes to the growth of arterial atherosclerotic lesions by promoting the proliferation of vascular smooth muscle cells and the migration of smooth muscle cells to endothelial cells. Moreover Lp(a) inhibits plasminogen binding to the surfaces of endothelial cells and decreases the activity of fibrin-dependent tissue-type plasminogen activator. Lp(a) may act as a proinflammatory mediator that augments the lesion formation in atherosclerotic plaques. Elevated serum Lp(a) is an independent predictor of coronary artery disease and myocardial infarction. Furthermore, Lp(a) levels should be a marker of restenosis after percutaneous transluminal coronary angioplasty, saphenous vein bypass graft atherosclerosis, and accelerated coronary atherosclerosis of cardiac transplantation. Finally, the possibility that Lp(a) may be a risk factor for ischemic stroke has been assessed in several studies. Recent findings suggest that Lp(a)-lowering therapy might be beneficial in patients with high Lp(a) levels. A future therapeutic approach could include apheresis in high-risk patients in order to reduce major coronary events.

show abstract

Section: Lp(a) and Cardiovascular Diseasesmentioning

confidence: 99%

Lipoprotein(a) in Cardiovascular Diseases

Malaguarnera

Vacante

Russo

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Next to cardiac manifestations it could be demonstrated that elevated LPA levels are associated with extracardiac arteriosclerosis like peripheral arterial disease and stenosis of the arteria carotis [18, 19]. Von Depka reports about elevated LPA levels as an independent risk factor for venous thromboembolism [11].…”

Section: Introductionmentioning

confidence: 99%

Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease

Buuren

Horstkotte

Knabbe

et al. 2017

Clin Res Cardiol Suppl

View full text Add to dashboard Cite

BackgroundRecently it has been demonstrated that elevated lipoprotein (a) (LPA) levels are associated with an increased risk of cardiovascular disease across multiple ethnic groups. However, there is only scanty data about the incidence of elevated LPA levels in different patient cohorts. As a consequence, we aimed to examine whether patients with elevated LPA levels might be seen more often in a cardiovascular center in comparison to the general population.MethodsWe reviewed LPA concentrations of 52,898 consecutive patients who were admitted to our hospital between January 2004 and December 2014. We subdivided them into different groups according to their LPA levels. Data was compared to available information in medical literature.Results26.4% of the patients had LPA levels >30 mg/dl which is in line with the data from literature. Mean level of LPA concentration in our study was twice as high in comparison to the general population (25.8% vs. 13.3%). 4.6% had LPA levels >98 mg/dl (general population <0.3%).ConclusionIn patients admitted to a cardiovascular center the proportion of LPA >30 mg/dl is comparable to the general population but mean levels over all are twice as high and the proportion of patients with LPA levels of >98 mg/dl is extremely higher.

show abstract

“…Currently, we found that Lp(a) level was associated with coronary but not carotid atherosclerosis. The exact mechanism with regarding this disparity in carotid and coronary arteries is unknown, while a large number of studies have suggested that Lp(a) exerts atherogenic property due to its cholesterol‐rich particle, the prothrombotic, and proinflammatory effects . In other words, in spite of the similarities between coronary and carotid atherosclerosis including sharing partial conventional risk factors, the exact correspondence between the two arteries remains unclear and thus the specific effects of Lp(a) on coronary and carotid arteries may be different .…”

Section: Discussionmentioning

confidence: 99%